The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation
Background: In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage. In addition, there are no reported prognostic biomarkers of disease severity in drug erupt...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-01-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893017300655 |
| _version_ | 1811230738254659584 |
|---|---|
| author | Takayoshi Komatsu-Fujii Yuko Chinuki Hiroyuki Niihara Kenji Hayashida Masataka Ohta Ryota Okazaki Sakae Kaneko Eishin Morita |
| author_facet | Takayoshi Komatsu-Fujii Yuko Chinuki Hiroyuki Niihara Kenji Hayashida Masataka Ohta Ryota Okazaki Sakae Kaneko Eishin Morita |
| author_sort | Takayoshi Komatsu-Fujii |
| collection | DOAJ |
| description | Background: In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage. In addition, there are no reported prognostic biomarkers of disease severity in drug eruptions. The aim of this study was to test whether the thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption can serve as a prognostic biomarker of systemic inflammation.
Methods: Study participants included 76 patients who received a diagnosis of a drug eruption, one of the following: drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, maculopapular exanthema, and erythema multiforme. Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) was eliminated in this study because scoring system for evaluating the severity was established. Correlation coefficients between serum TARC levels and indicators of systemic inflammation, including the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, modified systemic inflammatory response syndrome (mSIRS) score, and C-reactive protein in serum were evaluated.
Results: Serum TARC levels positively correlated with the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, mSIRS score, C-reactive protein, albumin, white blood cell count, body temperature, and pulse rate. TARC levels negatively correlated with systolic blood pressure. Among these parameters, the mSIRS score showed strong correlation (correlation coefficient: 0.68).
Conclusions: Serum TARC levels correlate well with indicators of systemic inflammation and of disease severity among patients with a drug eruption except SJS/TEN. Serum TARC may be a prognostic biomarker of severity of inflammation in drug eruptions. |
| first_indexed | 2024-04-12T10:34:01Z |
| format | Article |
| id | doaj.art-c8c0776f79c542d5a280bb5899a69939 |
| institution | Directory Open Access Journal |
| issn | 1323-8930 |
| language | English |
| last_indexed | 2024-04-12T10:34:01Z |
| publishDate | 2018-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Allergology International |
| spelling | doaj.art-c8c0776f79c542d5a280bb5899a699392022-12-22T03:36:47ZengElsevierAllergology International1323-89302018-01-01671909510.1016/j.alit.2017.06.001The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammationTakayoshi Komatsu-Fujii0Yuko Chinuki1Hiroyuki Niihara2Kenji Hayashida3Masataka Ohta4Ryota Okazaki5Sakae Kaneko6Eishin Morita7Department of Dermatology, Shimane University Faculty of Medicine, Izumo, JapanDepartment of Dermatology, Shimane University Faculty of Medicine, Izumo, JapanDepartment of Dermatology, Shimane University Faculty of Medicine, Izumo, JapanDepartment of Dermatology, Shimane University Faculty of Medicine, Izumo, JapanDepartment of Dermatology, Shimane University Faculty of Medicine, Izumo, JapanDepartment of Laboratory Medicine, Shimane University Hospital, Izumo, JapanDepartment of Dermatology, Shimane University Faculty of Medicine, Izumo, JapanDepartment of Dermatology, Shimane University Faculty of Medicine, Izumo, JapanBackground: In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage. In addition, there are no reported prognostic biomarkers of disease severity in drug eruptions. The aim of this study was to test whether the thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption can serve as a prognostic biomarker of systemic inflammation. Methods: Study participants included 76 patients who received a diagnosis of a drug eruption, one of the following: drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, maculopapular exanthema, and erythema multiforme. Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) was eliminated in this study because scoring system for evaluating the severity was established. Correlation coefficients between serum TARC levels and indicators of systemic inflammation, including the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, modified systemic inflammatory response syndrome (mSIRS) score, and C-reactive protein in serum were evaluated. Results: Serum TARC levels positively correlated with the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, mSIRS score, C-reactive protein, albumin, white blood cell count, body temperature, and pulse rate. TARC levels negatively correlated with systolic blood pressure. Among these parameters, the mSIRS score showed strong correlation (correlation coefficient: 0.68). Conclusions: Serum TARC levels correlate well with indicators of systemic inflammation and of disease severity among patients with a drug eruption except SJS/TEN. Serum TARC may be a prognostic biomarker of severity of inflammation in drug eruptions.http://www.sciencedirect.com/science/article/pii/S1323893017300655Drug eruptionGlasgow prognostic score (GPS)Systemic inflammatory response syndrome (SIRS)Neutrophil to lymphocyte ratio (NLR)Thymus and activation-regulated chemokine (TARC) |
| spellingShingle | Takayoshi Komatsu-Fujii Yuko Chinuki Hiroyuki Niihara Kenji Hayashida Masataka Ohta Ryota Okazaki Sakae Kaneko Eishin Morita The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation Allergology International Drug eruption Glasgow prognostic score (GPS) Systemic inflammatory response syndrome (SIRS) Neutrophil to lymphocyte ratio (NLR) Thymus and activation-regulated chemokine (TARC) |
| title | The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation |
| title_full | The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation |
| title_fullStr | The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation |
| title_full_unstemmed | The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation |
| title_short | The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation |
| title_sort | thymus and activation regulated chemokine tarc level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation |
| topic | Drug eruption Glasgow prognostic score (GPS) Systemic inflammatory response syndrome (SIRS) Neutrophil to lymphocyte ratio (NLR) Thymus and activation-regulated chemokine (TARC) |
| url | http://www.sciencedirect.com/science/article/pii/S1323893017300655 |
| work_keys_str_mv | AT takayoshikomatsufujii thethymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT yukochinuki thethymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT hiroyukiniihara thethymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT kenjihayashida thethymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT masatakaohta thethymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT ryotaokazaki thethymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT sakaekaneko thethymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT eishinmorita thethymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT takayoshikomatsufujii thymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT yukochinuki thymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT hiroyukiniihara thymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT kenjihayashida thymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT masatakaohta thymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT ryotaokazaki thymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT sakaekaneko thymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation AT eishinmorita thymusandactivationregulatedchemokinetarclevelinserumatanearlystageofadrugeruptionisaprognosticbiomarkerofseverityofsystemicinflammation |